Contract development and manufacturing organisations (CDMOs) KBI Biopharma and Argonaut Manufacturing Services have formed a strategic partnership to provide biopharmaceutical clients with comprehensive solutions from drug substance to drug product manufacturing.
The collaboration is set to streamline development and cGMP [current good manufacturing practice] processes for their clients.
The partnership will combine KBI's expertise in drug development and biologics manufacturing activities with Argonaut's sterile fill-finish operations expertise.
The collaboration aims to support clients in delivering clinical and commercial therapies to patients rapidly and safely.
Biopharmaceutical enterprises are anticipated to benefit from the expedited timelines and scalable manufacturing expertise provided by KBI and Argonaut.
Argonaut founder and CEO Wayne Woodard stated: “We believe this strategic alliance resolves a key issue for biopharmaceutical organisations as it greatly improves the alignment and integration between two complex and critical aspects of drug development and manufacturing.
“Biopharmaceutical companies will benefit from an integrated solution that is faster, more flexible and leverages the unique expertise of our two organisations.
“Argonaut’s fill-finish capabilities are scalable from first-in-human clinical material for rare diseases through commercial batches of approved products.”
Argonaut secured a capital investment in January 2023 to significantly expand the capacity of its manufacturing sites in Carlsbad, California, US.
KBI Biopharma president and CEO JD Mowery stated: “At KBI Biopharma, we have always been committed to delivering innovative solutions that accelerate the development and manufacturing of life-saving therapeutics.
“Our state-of-the-art facilities and world-class team have consistently pushed the boundaries of what is possible in biopharmaceutical development.”
Partners across the world are leveraging the technologies of KBI to progress more than 170 drug candidates in preclinical and clinical development and the production of ten commercial assets.
In September 2023, KBI unveiled its SUREmAb offering. This permits streamlined and cost-effective development and production of monoclonal antibodies.
